Nagasaki, Japan

Tatsufumi Nakamura

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Nagasaki University, Reqmed Company, Ltd.. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsufumi Nakamura. Retrieved from https://idiyas.com/inventor/tatsufumi-nakamura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Tatsufumi Nakamura

Introduction

Tatsufumi Nakamura is a notable inventor based in Nagasaki, Japan. He has made significant contributions to the field of medical treatments, particularly in relation to HTLV-I associated myelopathy.

Latest Patents

Nakamura holds a patent for an agent that treats HTLV-I associated myelopathy. This invention includes pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. Additionally, it provides a therapeutic agent aimed at improving movement disorders associated with HAM.

Career Highlights

Throughout his career, Nakamura has worked with prestigious institutions such as Nagasaki University and Reqmed Company, Ltd. His work has focused on developing innovative solutions for complex medical conditions.

Collaborations

Nakamura has collaborated with various professionals in his field, including his coworker Tadashi Matsumoto.

Conclusion

Tatsufumi Nakamura's contributions to medical innovation highlight the importance of research and development in treating challenging health issues. His work continues to impact the field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…